Serum Carbonic Anhydrase 9 Level is Associated With Postoperative Recurrence of Conventional Renal Cell Cancer

G, Li; Feng, Gang; Gentil-Perret, Anne; Genin, Christian; Tostain, Jacques

doi:10.1016/j.juro.2008.04.024

Cited by 81 publications

(58 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in accordance with the study of Li et al, who first reported a significant association between serum CA IX and stage, tumor grade and size in patients with CCRCC. In their study of 91 patients, the mean value of serum CA IX in patients with metastatic CCRCC (216.68±67.02 pg/ ml) was significantly higher than that in localized CCRCC (91.65±13.29 pg/ml) (19). Similar CA IX values for CCRCC patients (126.1 pg/ml) with the same commercial ELISA kit for CA IX were reported by Zhou et al (20).…”

Section: Discussionsupporting

confidence: 70%

“…However, the second study provides evidence that the estimated 5-year disease-free survival for patients with detectable CA9 mRNA in the peripheral blood was 39.5% in comparison with 88.1% for CA9-negative patients. Several studies have examined the potential clinical utility of s-CA IX in the serum from RCC patients for prognostic and predictive applications (18)(19)(20)(21)(22)(23). s-CA IX is a shorter form of CA IX (50/54 kDa) which is released into the culture medium or into the body fluids via a metalloprotease-dependent process regulated by TACE/ADAM17 (24).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

et al. 2012

View full text Add to dashboard Cite

Abstract. Carbonic anhydrase IX (CA IX) is regarded as one of the most prominent markers of tumor hypoxia with potential to serve as a diagnostic biomarker, prognostic indicator as well as tumor therapeutic target. The aim of the present study was to perform an in-depth analysis of CA IX expression in blood and tissue samples and to evaluate the significance of CA IX status for different renal cell carcinomas (RCCs). The expression of CA IX was determined in blood and tissue samples from 74 kidney cancer patients using reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), Western blotting (WB) and immunohistochemistry (IHC). The CA IX status was correlated with RCC type and tumor stage. IHC and WB provided evidence for a significantly higher expression of CA IX in clear cell RCC (CCRCC) specimens compared to other RCCs. RT-PCR assay revealed that 32.42% of all RCC patients possess CA9-positive cells in peripheral blood and three-quarters of CA9-positive patients were diagnosed with CCRCC. When the patients were subdivided according to tumor stage, decreased positivity was observed with higher tumor stage (50% in T1 vs. 17% in T3). Serum CA IX levels determined by ELISA were significantly higher in CCRCC patients than in non-CCRCC. A significant association between s-CA IX and CCRCC tumor stage was also determined (T1-87.51 vs. T3-341.98 pg/ml, p=0.046). We demonstrated that the CA IX expression profiles in blood and tissue samples from 74 kidney cancer patients are closely correlated with their histological subtypes. This is the first study reporting CA IX expression in blood and tissue samples from kidney cancer patients determined by four different methods.

show abstract

Section: Discussionsupporting

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Our study reports that the plasma CAIX level in NSCLC patients is significantly higher than in healthy individuals (Po0.001). Nevertheless, we showed that the plasma CAIX detected in patients with NSCLC is much lower than CAIX concentrations described in renal cell carcinoma, because the very high constitutive HIF-1a levels in these latter tumours and also differences in CAIX expression depending on the cell type (Li et al, 2008). Increased levels of plasma CAIX have been reported only in urological cancers (Zavada et al, 2003;Li et al, 2008;Hyrsl et al, 2009).…”

Section: Discussionmentioning

confidence: 64%

High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Carbonic anhydrase IX (CAIX) is an enzyme upregulated by hypoxia during tumour development and progression. This study was conducted to assess if the expression of CAIX in tumour tissue and/or plasma can be a prognostic factor in patients with non-small cell lung cancer (NSCLC). METHODS: Tissue microarrays containing 555 NSCLC tissue samples were generated for quantification of CAIX expression. The plasma level of CAIX was determined by ELISA in 209 of these NSCLC patients and in 58 healthy individuals. The CAIX tissue immunostaining and plasma levels were correlated with clinicopathological factors and patient outcome. RESULTS: CAIX tissue overexpression correlated with shorter overall survival (OS) (P ¼ 0.05) and disease-specific survival (DSS) of patients (P ¼ 0.002). The CAIX plasma level was significantly higher in patients with NSCLC than in healthy individuals (Po0.001). A high level of CAIX in the plasma of patients was associated with shorter OS (Po0.001) and DSS (Po0.001), mostly in early stage I þ II NSCLC. Multivariate Cox analyses revealed that high CAIX tissue expression (P ¼ 0.002) was a factor of poor prognosis in patients with resectable NSCLC. In addition, a high CAIX plasma level was an independent variable predicting poor OS (Po0.001) in patients with NSCLC. CONCLUSION: High expression of CAIX in tumour tissue is a predictor of worse survival, and a high CAIX plasma level is an independent prognostic biomarker in patients with NSCLC, in particular in early-stage I þ II carcinomas.

show abstract

“…Some molecules markers, such as CAIX (carbonic anhydrase IX), VEGF (vascular endothelial growth factor), GRP78 (glucose-regulated protein 78), CD146 had been found to be a powerful marker for the prognosis of RCC [15,16,17,18]. Circulating cfDNA, a biomarker that is easily accessible and preferably noninvasive, has been shown to have diagnostic and prognostic potential in RCC [12,19].…”

Section: Discussionmentioning

confidence: 99%

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

Wan

Zhu

Jiang³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Background: Circulating cell-free DNA (cfDNA) mostly originates from tumors and its level correlates with treatment. We assessed whether the level of plasma cfDNA could help monitor recurrence after nephrectomy. Methods: This study included 92 patients with clear cell renal cell carcinoma (cRCC). Quantitative real-time PCR was used to measure the level of plasma cfDNA before and after nephrectomy. Results: The pretreatment level of plasma cfDNA in patients with metastatic cRCC (6.04 ± 0.72) was significantly higher than in those with localized cRCC (5.29 ± 0.53, p = 0.017) or controls (0.65 ± 0.29, p < 0.001). Of patients with localized cRCC, those with recurrence had a significantly higher plasma cfDNA level than those without (p = 0.024). The patients with a high plasma cfDNA level had a significantly higher recurrence rate than those with a low plasma cfDNA level before and after nephrectomy (p = 0.018). Conclusion: The level of plasma cfDNA may be useful as a tool to monitor patients during follow-up and guide further diagnostic work-up for the detection of recurrence.

show abstract

Serum Carbonic Anhydrase 9 Level is Associated With Postoperative Recurrence of Conventional Renal Cell Cancer

Abstract: Our data suggest that serum carbonic anhydrase 9 is increased as the tumor progression occurs. A high carbonic anhydrase 9 level is associated with postoperative recurrence.

Cited by 81 publications

References 13 publications

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer

Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About